Last reviewed · How we verify
Prevention of COVID-19 in individuals 6 months through 4 years of age
Approved treatments
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg · Pfizer
Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus. - BNT162b2 Bivalent (WT/OMI BA.1) · Pfizer
- BNT162b2 vaccine · Vaxxinity, Inc.
Not specified - Investigational COVID-19 Vaccine · BioNTech
- Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) · Pfizer
- BNT162b2 (Omi KP.2) · Pfizer Inc.
- BNT162b2 BA.4/5 bivalent · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of COVID-19 in individuals 6 months through 4 years of age patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of COVID-19 in individuals 6 months through 4 years of age treatment landscape brief
- Prevention of COVID-19 in individuals 6 months through 4 years of age treatment updates RSS
Frequently asked questions about Prevention of COVID-19 in individuals 6 months through 4 years of age
What drugs treat Prevention of COVID-19 in individuals 6 months through 4 years of age?
Tracked treatments include BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 vaccine, Investigational COVID-19 Vaccine, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), BNT162b2 (Omi KP.2), BNT162b2 BA.4/5 bivalent.
What is the treatment for Prevention of COVID-19 in individuals 6 months through 4 years of age?
Standard treatment for Prevention of COVID-19 in individuals 6 months through 4 years of age includes BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 vaccine, Investigational COVID-19 Vaccine, Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of COVID-19 in individuals 6 months through 4 years of age patent cliff · Prevention of COVID-19 in individuals 6 months through 4 years of age CI report
- Treatment: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg · Pfizer
- Treatment: BNT162b2 Bivalent (WT/OMI BA.1) · Pfizer
- Treatment: BNT162b2 vaccine · Vaxxinity, Inc.
- Treatment: Investigational COVID-19 Vaccine · BioNTech
- Treatment: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing